Payment overview · 2025
General Payments
$71.15
4 reported records · 4 companies
Healthcare provider profile · identity verified
David H Arnold, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GENEVA, AL · NPI 1891794822
Verified facts
What the public records show
CMS Open Payments records show David H Arnold, M.D. received $71.15 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.87 | 33.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.64 | 23.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.61 | 21.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.03 | 21.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $71.15 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 150 |
| Gabapentin | Gabapentin | 424 | 101 |
| Losartan Potassium | Losartan Potassium | 377 | 116 |
| Tramadol Hcl | Tramadol Hcl | 320 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 87 |
| Lisinopril | Lisinopril | 295 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 268 | 49 |
| Omeprazole | Omeprazole | 266 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 63 |
| Sertraline Hcl | Sertraline Hcl | 170 | 51 |
| Alprazolam | Alprazolam | 160 | 30 |
| Furosemide | Furosemide | 155 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 50 |
| Meloxicam | Meloxicam | 148 | 59 |
| Metformin Hcl | Metformin Hcl | 141 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 41 |
| Potassium Chloride | Potassium Chloride | 134 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 17 |
| Trazodone Hcl | Trazodone Hcl | 118 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 38 |
| Glimepiride | Glimepiride | 111 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 36 |
| Prednisone | Prednisone | 105 | 66 |
| Baclofen | Baclofen | 102 | 38 |
| Januvia | Sitagliptin Phosphate | 100 | 24 |
| Ozempic | Semaglutide | 97 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 26 |
| Simvastatin | Simvastatin | 89 | 32 |
| Pregabalin | Pregabalin | 88 | 16 |
| Montelukast Sodium | Montelukast Sodium | 83 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 29 |
| Allopurinol | Allopurinol | 78 | 24 |
| Carvedilol | Carvedilol | 75 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 23 |
| Temazepam | Temazepam | 71 | suppressed |
| Bumetanide | Bumetanide | 70 | 24 |
| Jardiance | Empagliflozin | 70 | 15 |
| Doxepin Hcl | Doxepin Hcl | 69 | 11 |
| Metformin Hcl Er | Metformin Hcl | 65 | 27 |
| Mounjaro | Tirzepatide | 64 | 14 |
| Buspirone Hcl | Buspirone Hcl | 63 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 19 |
| Lorazepam | Lorazepam | 62 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 18 |
| Estradiol | Estradiol | 58 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 57 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 15 |
| Clonidine Hcl | Clonidine Hcl | 55 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 52 | 13 |
| Cefuroxime | Cefuroxime Axetil | 50 | 44 |
| Celecoxib | Celecoxib | 50 | 18 |
| Eliquis | Apixaban | 50 | 12 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 14 |
| Mirtazapine | Mirtazapine | 47 | 18 |
| Promethazine Hcl | Promethazine Hcl | 46 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 20 |
| Nitroglycerin | Nitroglycerin | 45 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 37 |
| Famotidine | Famotidine | 43 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Ibuprofen | Ibuprofen | 42 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 18 |
| Amoxicillin | Amoxicillin | 37 | 24 |
| Azithromycin | Azithromycin | 37 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 23 |
| Cephalexin | Cephalexin | 36 | 29 |
| Fluconazole | Fluconazole | 36 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 11 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Atenolol | Atenolol | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 32 | 13 |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 11 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Naproxen | Naproxen | 29 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 25 | 18 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Cilostazol | Cilostazol | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $71.15 · 4 records | AstraZeneca Pharmaceuticals LP | Cologuard Collection Kit, FARXIGA, MOUNJARO, NURTEC ODT, PAXLOVID | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error